Edition:
United States

People: Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

2.92USD
22 Apr 2019
Change (% chg)

-- (--)
Prev Close
$2.92
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
95,373
52-wk High
$6.91
52-wk Low
$2.40

Adams, Julian 

Dr. Julian Adams is Director of the Company. He has served since 2007 as the President of Research and Development at Infinity Pharmaceuticals, where he has held several roles since joining the company in 2003, including Chief Scientific Officer, and currently leads the full spectrum of Infinity's drug discovery, preclinical and clinical development, and regulatory affairs activities. During his career, Dr. Adams has had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy, and the drug Viramune® (nevirapine) for HIV. Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade ® from the International Myeloma Foundation. Dr. Adams is an inventor on more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --